Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating acute and overuse sprain and strain using hyaluronic acid

An acute and useful technology, applied in the field of hyaluronic acid in the treatment of sprains and strains in animals and humans, can solve the problems of insufficient effect, limited curative effect, and complicated treatment process.

Active Publication Date: 2006-11-08
罗伯特·约翰·佩特雷拉
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although it is mentioned that intra-articular injection of HA can be used in various situations, the treatment process is very complicated due to the difficulty in positioning the joint cavity during intra-articular injection
Improper injections can lead to various complications
[0004] Most known medical treatments for sprains and strains, whether anti-inflammatory and / or analgesic, have proven inadequate
Most treatments have limited efficacy or significant side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] HA preparation

[0055]The average molecular weight of HA may be 30-750 kDa, 50-750 kDa, 500-750 kDa, 30 kDa to above 750 kDa, or greater than 750 kDa. None of these HA forms are HA types smaller than 30 kDa. Other forms that can be used in the present invention include HA with an average molecular weight of 30-750 kDa, 50-750 kDa, 500-750 kDa, 30 kDa to above 750 kDa, or greater than 750 kDa, and also include HA with a molecular weight of less than 30 kDa, including HA with a molecular weight of 0.3-30 kDa, HA of 10-30 kDa or about 24 kDa. In one embodiment, the average molecular weight of the HA used in the present invention is 30-750kDa, 50-750kDa, 500-750kDa, 30kDa to above 750kDa, or greater than 750kDa, including HA types with an average molecular weight of about 24kDa.

[0056] Another form of HA that can be used in the present invention has an average molecular weight of less than 50 kDa or less than 30 kDa. In one embodiment, the average molecular weight of ...

Embodiment 2

[0059] Efficacy of periarticular administration of HA on ankle sprains

[0060] This study was conducted in accordance with Good Clinical Practice (GCP) and in accordance with the requirements of the International Conference on Harmonization and the Declaration of Helsinki. On the first day (within 48 hours of injury), after the patient signed an informed consent form, the patients were examined to assess whether they met all inclusion criteria and had no exclusion criteria. Inclusion criteria included: age 18 years or older, first-degree or second-degree lateral ankle sprain and administration of study drug within 48 hours, moderate (45-60mm) as assessed by the 100mm visual analogue scale after the patient was bearing full weight, or Severe (greater than 60mm) ankle pain. This visual analogue scale was used throughout the clinical investigation. Patients with bilateral ankle sprains, ipsilateral knee injuries, third-degree sprains, or previous ankle sprains within the previ...

Embodiment 3

[0070] Efficacy of periarticular (peritendon) injection of HA with an average molecular weight of 500-750kDa on iliotibial band syndrome

[0071] Eight young and middle-aged patients with symptoms of unilateral pain at the proximal end and firm iliotibial band (ITB) syndrome for at least 3 months (3-9 months) using negative hip pathology studies (radiographs) test. Patients were injected with 2.5 cc of 10 mg / ml HA with a molecular weight of 500-6800 kDa at the beginning and on days 7 and 14 after the initial injection. HA injections were performed without anesthesia using a 25 gauge needle and a 3cc syringe. Clinical assessments were performed prior to treatment 1, 7 and 14 (+ / - 2 days). Efficacy measurements included: 1) patient weight-bearing assessment using a 100mm VAS; 2) comprehensive assessment of patient efficacy (absolute scale 1-5); 3) patient satisfaction with the injection course using a 10-point VAS; and 4) use of Ober ITB elasticity (positive or negative) as m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method for treating acutely or chronically injured soft tissue in an animal or human, the method comprising administering a therapeutically effective amount of HA around the injured soft tissue. The method is useful for the treatment of sprain, strain and shin splints in an animal or human by periarticular administration of a composition comprising HA and a pharmaceutically acceptable carrier. The present invention can be used to potentiate the concomitant treatment of sprain or strain with other therapies.

Description

technical field [0001] The present invention relates to the use of hyaluronic acid to treat sprains and strains in animals and humans. Background technique [0002] Millions of people are treated each year for acute or overuse injuries to ligaments (sprains) or tendon structures (strains). Sprains can be categorized as grade 1 (mild ligament tear), grade 2 (major ligament tear, blood clot, and moderate functional impairment), and grade 3 sprain (complete ligament tear, loss of function and mechanical stability). Symptoms include pain, heat, redness, swelling, and loss of function. Sprain treatment is mainly anti-inflammatory and analgesic. Mild to moderate sprains (Grade 1 and 2) are usually treated at home with immobilization, cold, compression, and elevation of the sprained area (this is known as "RICE" therapy, RICE stands for rest -ice-compression-elevation), and take non-steroidal anti-inflammatory drugs (NSAIDs) anti-inflammatory analgesia, such as aspirin, ibuprofe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/728A61K45/06A61P19/04A61P21/00
CPCA61K31/728A61K45/06A61P19/00A61P19/02A61P19/04A61P21/00A61P43/00A61K2300/00
Inventor 罗伯特·约翰·佩特雷拉
Owner 罗伯特·约翰·佩特雷拉
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com